Questcors Q1 tal var umiddelbart ved første indskydelse negativ læsning, hvilket også fik aktien til at gå ned i aftermarkedet. Dette rettede sig dog hurtigt og aktien er steget meget de sidste par dage.

Dette skyldes nogle væsentlige oplysninger fra regnskabet og CC der går udover tallene.

– Integrationen af BioVetra er gået godt, og man forventer omsætningsstigning herfra hen mod slutningen af året.

– På trods af at der kun blev solgt 4.111 vials af Achtar mod 6.330 i Q4 2012, skyldes dette sæsonudsving mv., hvilket også gjorde at Q4 2012 var EKSTRA stærkt en normalt. Det spændende er dog at Questcor rapporterer om at vials i April har været den stærkeste måned nogensinde med 2500 vials solgt og at maj samtidig også tegner godt. Så på trods af lidt nedgang i Q1 har Questcor allerede genetableret væksten og sat ny vials rekord i maj måned.

Men disse nye rekorder vil Questcor kunne rapporterer EPS tal på 1-1,25 per kvartal pt. Dette svarer annualiseret til 4-5 i EPS, hvilket skal holdes op imod en aktiekurs på omkring 33.



Questcor Reports First Quarter Financial Results

– Net Sales Increase 41% Year Over Year; Down Sequentially – – April Vial Shipments Rebound Significantly Establishing a New Monthly Record- – Prescription Levels in Rheumatology Increasing – – Phase 2 Clinical Trial of Acthar in ALS to Start under FDA Accepted IND –

ANAHEIM, Calif., April 30, 2013 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2013. Financial results include BioVectra Inc. since January 18, 2013.

   Three Months Ended 03/31/13    Three Months Ended 03/31/12 Percentage Change
Net Sales $135.1 Million $96.0 Million 41%
GAAP Diluted EPS $0.65 $0.58 12%
Non-GAAP Diluted EPS $0.76 $0.61 25%

Net sales for the first quarter of 2013 were $135.1 million, with BioVectra contributing $8.4 million. Year-over-year net sales grew 41 percent from $96.0 million in the first quarter of 2012. Net sales growth was driven by the expanded usage of H.P. Acthar® Gel (repository corticotropin injection) by nephrologists in the treatment of nephrotic syndrome (NS) and by rheumatologists in the treatment of dermatomyositis, polymyositis, systemic lupus erythematosus, and rheumatoid arthritis, as well as continued prescribing by neurologists in the treatment of multiple sclerosis (MS) exacerbations and infantile spasms (IS).

Net sales in the first quarter of 2013 were negatively impacted by the effects of several transitional events, including: distribution channel disruptions associated with implementing the Medicaid rebate change, the timing of Acthar orders that were received and filled at the end of fourth quarter 2012 and the introduction of a new reimbursement support center. This was partially offset by the positive impact of a lower Medicaid rebate rate and the acquisition of BioVectra. Based on its analysis of prescription trends, Questcor believes that the decline in its net sales from the fourth quarter of 2012 to the first quarter of 2013 reflected these transitional issues, as well as a reduction in the number of prescriptions of Acthar to treat MS exacerbations. The Company believes that insurance coverage for  Acthar continues to remain favorable, when Acthar is prescribed for on-label indications for patients in need of an additional FDA-approved treatment alternative.

Questcor shipped 4,830 vials of Acthar during the first quarter of 2013 compared to 4,111 vials in the first quarter of 2012 and 6,330 vials in the fourth quarter of 2012. The Company shipped 2,550 vials of Acthar to its distributor in April 2013, which is a record number of vials shipped in a single month.  The Company believes this strong demand primarily reflects the transitional nature of the factors that negatively impacted first quarter net sales. As the Company has previously disclosed, monthly and quarterly vial shipments are subject to significant variation due to the size and timing of individual orders received from Questcor’s distributor. The timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter. For example, in late December  2012, Questcor received and shipped two orders that represented 360 vials of Acthar. The Company believes that investors should consider the Company’s results over several quarters when analyzing the Company’s performance.

GAAP earnings for the first quarter of 2013 were $0.65 per diluted common share, compared to $0.58 per diluted common share for last year’s comparable quarter. Non-GAAP earnings for the quarter ended March 31, 2013 were $0.76 per diluted common share and exclude non-cash share-based compensation expense, impairment of purchased technology, foreign currency transaction losses, interest expense related to our contingent consideration in conjunction with our acquisition of BioVectra, non-cash compensation expense and depreciation and amortization expense. Non-GAAP earnings for the year ago quarter were $0.61 per  diluted common share. The reconciliation between GAAP and Non-GAAP financial measures are provided with the financial tables included with this release.

“Our first quarter results were below our expectations,” said Don M. Bailey, President and CEO of Questcor. “However, vial shipment activity and prescription levels in MS and rheumatology in late March and throughout April appear to indicate that positive sales momentum has returned. In particular, we note that our newest initiative related to the promotion of Acthar for dematomyositis and polymyositis is off to a strong start.”

Mr. Bailey continued, “In the first quarter, we made several operational changes aimed at ensuring and improving the delivery of Acthar for patients who rely on this important drug. We continue to seek to improve our business operations in order to benefit both Acthar patients and our shareholders by establishing a solid foundation for potential additional growth.”

“Total new paid prescriptions for Acthar were approximately 1,725 to 1,750 in the first quarter, an increase of about 16% year-over-year and a decrease of about 9% sequentially,” commented Steve Cartt, Chief Operating Officer of Questcor. “New paid prescriptions for NS, which represent about half of our Acthar business, were about 385-395 in the quarter, up about 56% year-over-year and up about 5% over the fourth quarter of 2012. New paid prescriptions for MS, which represent about a quarter of our Acthar business, were about 1,015 to 1,025, roughly flat year-over-year and down 17% from the prior quarter. New paid prescriptions for IS were 155 to 165. Net sales related to IS were positively influenced by the reduction of the Medicaid rebate in the quarter. New paid prescriptions for the on-label  rheumatology indications were 140-150, up about 58% sequentially.”

Mr. Cartt continued, “Consistent with the level of our vial sales in April, new paid prescription activity in April has been robust. While the second quarter is only about one-third complete, NS continues to grow, MS is on track to recover from first quarter softness, and rheumatology may well be up sharply from the first quarter.”

About Investor1989

Investor in stocks in about 5 years with some very good profits. Focusing on Biotech and Value stocks. Active investor...


Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.